Renal Ischemia-Reperfusion Injury Mechanisms and Therapeutic Interventions

Renal ischaemia–reperfusion injury (RIRI) arises when blood flow to the kidney is interrupted and then restored, triggering a cascade of cellular and molecular events that culminate in acute kidney injury (AKI). Initial vascular constriction and endothelial dysfunction reduce microcirculatory perfusion, while sudden reoxygenation generates reactive oxygen species that overwhelm antioxidant defences. Mitochondrial damage, calcium overload and activation of inflammatory pathways—especially via NF-κB and cytokine release—further exacerbate tubular epithelial and endothelial cell death through apoptosis, necrosis and regulated necroptosis. In parallel, maladaptive repair and fibroblast activation set the stage for chronic kidney disease. Therapeutic strategies under active investigation include pharmacological modulation of oxidative stress and inflammation, epigenetic regulation, targeted activation of cytoprotective nuclear receptors (such as PPARγ), enhancement of autophagy and drug repurposing to accelerate translation. Preclinical successes in small molecules, biologics and gasotransmitters are now guiding early clinical trials, reflecting the global imperative to mitigate RIRI in transplantation, cardiovascular surgery and critical care.

Research from Nature Portfolio

Recent studies have explored repurposing of metformin and colchicine in murine models of renal ischaemia–reperfusion. Pre-emptive administration of either agent reduced serum creatinine, improved histological injury scores and enhanced autophagic protein expression, indicating protection of tubular epithelial integrity. Metformin’s benefits were linked to AMPK-mediated autophagy, whereas colchicine modulated inflammatory cell infiltration in the renal parenchyma. However, when administered chronically after acute injury in a reduced-mass kidney model, neither drug prevented fibrotic progression and colchicine even aggravated ischaemic phenotypes. These findings underscore the divergent effects of drug interventions in acute versus chronic phases and highlight the necessity of considering baseline renal status in therapeutic repurposing.

Renal Ischemia-Reperfusion Injury Mechanisms and Therapeutic Interventions publication trend

The graph below shows the total number of articles in renal ischemia-reperfusion injury mechanisms and therapeutic interventions across all publications each year (not limited to Nature Index journals).

Technical terms

Ischaemia–reperfusion injury: Tissue damage caused by restoration of blood supply after a period of ischaemia, leading to oxidative stress and inflammation.

Acute kidney injury (AKI): Rapid decline in renal function characterised by rising serum creatinine and reduced urine output over hours to days.

Autophagy: Lysosome-mediated degradation of damaged organelles and proteins, serving as a cytoprotective recycling mechanism under stress.

Oxidative stress: Cellular damage arising from an imbalance between generation of reactive oxygen species and antioxidant defence mechanisms.

Peroxisome proliferator-activated receptor γ (PPARγ): A nuclear receptor that regulates lipid metabolism, inflammation and cell survival, implicated in renoprotective signalling.

References

1. Repurposing of metformin and colchicine reveals differential modulation of acute and chronic kidney injury. Scientific Reports (2020).
2. DNA demethylase Tet2 suppresses cisplatin-induced acute kidney injury. Cell Death Discovery (2021).
3. Protective Effects of PPARγ on Renal Ischemia‐Reperfusion Injury by Regulating miR‐21. Oxidative Medicine and Cellular Longevity (2022).
4. Pioglitazone Ameliorates Renal Ischemia-Reperfusion Injury via Inhibition of NF-κB Activation and Inflammation in Rats. Frontiers in Physiology (2021).